XBiotech (XBIT) director granted 51,000 options at $2.64

XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share.

Accepted by SEC EDGAR 11/12/2025 - 09:54 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.

Insider Trade Summary

Grant/Award: 51,000 shares

Grant/Award 1 txn

Insider Soffer David Spencer

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option	51,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option — 51,000 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XBiotech (XBIT) report in this Form 4?

A director, David Soffer, reported receiving 51,000 nonstatutory stock options at an exercise price of $2.64 per share.

When were the XBiotech options granted to the director?

The options were granted on October 1, 2025.

What is the vesting schedule for the 51,000 XBiotech options?

They vest in two equal portions at four months and ten months from the grant date.

When do the reported XBiotech stock options expire?

They expire on October 1, 2035, ten years from the grant date.

How many derivative securities does the reporting person own after the transaction?

The filing shows 51,000 derivative securities beneficially owned, held directly.

Under which plan were the XBiotech options granted?

The options were granted under the company’s 2025 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soffer David Spencer

(Last) (First) (Middle)

1910 SOMMERFELD AVE

(Street)

SASKATOON A9 S7J 2E3

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [ XBIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option	$2.64	10/01/2025		A		51,000		02/01/2025	10/01/2035	Common Stock	51,000	$0	51,000	D

Explanation of Responses:

Remarks:

On October 1, 2025 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2025 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at four month and ten month from the Grant Date with an expiry of ten years from the Grant Date.David

	David Soffer	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.